Prita Riana Asih
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Prita Riana Asih has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Ralph N. Martins
Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia
17 shared publications - Hamid R. Sohrabi
Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA 6150, Australia
14 shared publications - Pratishtha Chatterjee
Florey Institute of Neuroscience and Mental Health University of Melbourne Parkville Victoria Australia
13 shared publications - Kathryn Goozee
Department of Biomedical Sciences, Macquarie University, North Ryde, Australia
10 shared publications Kevin Taddei
School of Medical and Health Sciences Edith Cowan University, Patricia Sarich Neuroscience Research Institute Nedlands WA Australia
10 shared publicationsHenrik Zetterberg
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
7 shared publications
Latest Publications
- 9 December 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (2) , 832-844
Plasma soluble TREM2 is associated with plasma pTau-181 and pTau-231 in cognitively normal older adults at risk of Alzheimer's disease
Background: CSF and blood soluble TREM2 (sTREM2) levels have been found to increase at early stage of Alzheimer's disease (AD). The relationships between sTREM2, AD-related biomarkers, and other neuroinflammation biomarkers remain unclear. Moreover, the impact of rare variants in TREM2 gene (R47H/R62H), which are associated with increased risk of AD, on plasma sTREM2 has not been elucidated. Objective: Investigate the association of plasma sTREM2 levels with brain amyloid-β (Aβ) load and AD-related blood biomarkers, i.e., phosphorylated tau (pTau)-181, pTau-231, GFAP, NFL, and other neuroinflammation and peripheral inflammation markers in cognitively normal (CN) older adults at risk of AD (CN Aβ+) compared to CN Aβ-, including the effect of AD-linked TREM2 rare variants. Methods: Plasma sTREM2 concentrations were measured by MesoScale Discovery (MSD) assay from the KARVIAH cohort. Participants underwent cognitive tests and PET amyloid imaging. Genetic data and blood biomarkers were included for correlation analysis. Associations with plasma sTREM2 were investigated upon stratification by PET-Aβ load SUVR ((CN Aβ- (n = 65) and CN Aβ+ (n = 35)) as the main analysis. A subgroup analysis based on the TREM2 R47H and R62H genotype was conducted as exploratory analysis. Results: Plasma sTREM2 positively correlated with plasma pTau181, and pTau231 in CN Aβ+ group. Plasma sTREM2 positively correlated with serum microglial kynurenine pathway metabolites. Plasma sTREM2 and brain Aβ load were higher in R47H TREM2 carriers compared to non-carriers. Conclusions: Our findings suggest plasma sTREM2 relates to downstream tau processes in amyloid-positive individuals, providing novel insights into the roles of peripheral TREM2 signaling that reflects microglial activity in early AD neuropathological development.
- 9 December 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 109 (2) , 832-844
Plasma soluble TREM2 is associated with plasma pTau-181 and pTau-231 in cognitively normal older adults at risk of Alzheimer's disease
Background: CSF and blood soluble TREM2 (sTREM2) levels have been found to increase at early stage of Alzheimer's disease (AD). The relationships between sTREM2, AD-related biomarkers, and other neuroinflammation biomarkers remain unclear. Moreover, the impact of rare variants in TREM2 gene (R47H/R62H), which are associated with increased risk of AD, on plasma sTREM2 has not been elucidated. Objective: Investigate the association of plasma sTREM2 levels with brain amyloid-β (Aβ) load and AD-related blood biomarkers, i.e., phosphorylated tau (pTau)-181, pTau-231, GFAP, NFL, and other neuroinflammation and peripheral inflammation markers in cognitively normal (CN) older adults at risk of AD (CN Aβ+) compared to CN Aβ-, including the effect of AD-linked TREM2 rare variants. Methods: Plasma sTREM2 concentrations were measured by MesoScale Discovery (MSD) assay from the KARVIAH cohort. Participants underwent cognitive tests and PET amyloid imaging. Genetic data and blood biomarkers were included for correlation analysis. Associations with plasma sTREM2 were investigated upon stratification by PET-Aβ load SUVR ((CN Aβ- (n = 65) and CN Aβ+ (n = 35)) as the main analysis. A subgroup analysis based on the TREM2 R47H and R62H genotype was conducted as exploratory analysis. Results: Plasma sTREM2 positively correlated with plasma pTau181, and pTau231 in CN Aβ+ group. Plasma sTREM2 positively correlated with serum microglial kynurenine pathway metabolites. Plasma sTREM2 and brain Aβ load were higher in R47H TREM2 carriers compared to non-carriers. Conclusions: Our findings suggest plasma sTREM2 relates to downstream tau processes in amyloid-positive individuals, providing novel insights into the roles of peripheral TREM2 signaling that reflects microglial activity in early AD neuropathological development.
- Open Access
Plasma soluble TREM2 is associated with plasma pTau-181 and pTau-231 in cognitively normal older adults at risk of Alzheimer’s disease
Background: CSF and blood soluble TREM2 (sTREM2) levels have been found to increase at early stage of Alzheimer’s Disease (AD). The relationships between sTREM2, AD-related biomarkers, and other neuroinflammation biomarkers remain unclear. Moreover, the impact of rare variants in TREM2 gene (R47H/R62H), which are associated with increased risk of AD, on plasma sTREM2 has not been elucidated. Objective: Investigate the association of plasma sTREM2 levels with brain Aβ load and AD-related blood biomarkers such as phosphorylated tau (pTau)-181, pTau-231, GFAP, NFL, and other neuroinflammation and peripheral inflammation markers in cognitively normal (CN) older adults at risk of AD (CN Aβ+) compared to CN Aβ-, including the effect of AD-linked TREM2 rare variants. Methods: Plasma sTREM2 concentrations were measured by MesoScale Discovery (MSD) assay from the KARVIAH cohort. Participants underwent cognitive tests and PET amyloid imaging. Genetic data and blood biomarkers were included for correlation analysis. Associations with plasma sTREM2 were investigated upon stratification by PET-Aβ load SUVR ((CN Aβ- (n=65) and CN Aβ+ (n=35)) as the main analysis. A subgroup analysis based on the TREM2 R47H genotype was carried out as exploratory analysis. Results: Plasma sTREM2 positively correlated with plasma pTau181, and pTau231 in CN Aβ+ group. Plasma sTREM2 positively correlated with serum microglial kynurenine pathway metabolites. Plasma sTREM2 and brain Aβ load were higher in R47H TREM2 carriers compared to non-carriers. Conclusions: Plasma sTREM2, a marker of microglia activation, is associated with plasma pTau181 and 231 in cognitively normal older adults at risk of AD, with higher plasma sTREM2 levels in R47H TREM2 carriers.
Open AccessPlasma soluble TREM2 is associated with plasma pTau-181 and pTau-231 in cognitively normal older adults at risk of Alzheimer’s disease
Background: CSF and blood soluble TREM2 (sTREM2) levels have been found to increase at early stage of Alzheimer’s Disease (AD). The relationships between sTREM2, AD-related biomarkers, and other neuroinflammation biomarkers remain unclear. Moreover, the impact of rare variants in TREM2 gene (R47H/R62H), which are associated with increased risk of AD, on plasma sTREM2 has not been elucidated. Objective: Investigate the association of plasma sTREM2 levels with brain Aβ load and AD-related blood biomarkers such as phosphorylated tau (pTau)-181, pTau-231, GFAP, NFL, and other neuroinflammation and peripheral inflammation markers in cognitively normal (CN) older adults at risk of AD (CN Aβ+) compared to CN Aβ-, including the effect of AD-linked TREM2 rare variants. Methods: Plasma sTREM2 concentrations were measured by MesoScale Discovery (MSD) assay from the KARVIAH cohort. Participants underwent cognitive tests and PET amyloid imaging. Genetic data and blood biomarkers were included for correlation analysis. Associations with plasma sTREM2 were investigated upon stratification by PET-Aβ load SUVR ((CN Aβ- (n=65) and CN Aβ+ (n=35)) as the main analysis. A subgroup analysis based on the TREM2 R47H genotype was carried out as exploratory analysis. Results: Plasma sTREM2 positively correlated with plasma pTau181, and pTau231 in CN Aβ+ group. Plasma sTREM2 positively correlated with serum microglial kynurenine pathway metabolites. Plasma sTREM2 and brain Aβ load were higher in R47H TREM2 carriers compared to non-carriers. Conclusions: Plasma sTREM2, a marker of microglia activation, is associated with plasma pTau181 and 231 in cognitively normal older adults at risk of AD, with higher plasma sTREM2 levels in R47H TREM2 carriers.
- Open Access
- 21 July 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (12) , 15576-15608
The Role of Glial Fibrillary Acidic Protein in the Neuropathology of Alzheimer’s Disease and Its Potential as a Blood Biomarker for Early Diagnosis and Progression
Alzheimer’s disease (AD) is a neurodegenerative disease characterised by neuropathological hallmarks, including extracellular amyloid plaques and neurofibrillary tangles. The disease is clinically defined by cognitive dysfunction, including learning, memory deficits, and behavioural changes. With the rising global prevalence of AD, early diagnosis is critical for implementing effective interventions before irreversible neuronal damage occurs. Biomarkers correlating amyloid deposition, tau pathology, neuroinflammation, and neurodegeneration are currently being investigated using cerebrospinal fluid analysis and positron emission tomography imaging. These methods are invasive or costly, limiting their widespread clinical utility. Blood-based biomarkers offer a promising alternative due to accessibility, cost-effectiveness, and feasibility for large-scale screening. Among blood-based biomarkers, plasma glial fibrillary acidic protein (GFAP) levels have gained interest in identifying individuals at risk of AD at preclinical stages. However, significant challenges remain, including methodological inconsistencies, analytical variability, and the need for standardisation across immunoassay platforms to ensure the clinical applicability of plasma GFAP measurement in AD diagnosis. Additionally, the specificity of GFAP for AD needs further evaluation, as increased plasma levels are also observed in other diseases. Similar issues are found with p-tau 217, the blood biomarker candidate for AD that has received the most attention. This review summarises the role of GFAP in the neuropathology of AD, provides evidence on plasma GFAP as an early blood biomarker for AD and identifies key knowledge gaps that need to be addressed. Future advancements in assay development and large-scale longitudinal studies are essential to validate its diagnostic and prognostic potential for community-based AD screening.
- 21 July 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (12) , 15576-15608
Open AccessThe Role of Glial Fibrillary Acidic Protein in the Neuropathology of Alzheimer’s Disease and Its Potential as a Blood Biomarker for Early Diagnosis and Progression
Alzheimer’s disease (AD) is a neurodegenerative disease characterised by neuropathological hallmarks, including extracellular amyloid plaques and neurofibrillary tangles. The disease is clinically defined by cognitive dysfunction, including learning, memory deficits, and behavioural changes. With the rising global prevalence of AD, early diagnosis is critical for implementing effective interventions before irreversible neuronal damage occurs. Biomarkers correlating amyloid deposition, tau pathology, neuroinflammation, and neurodegeneration are currently being investigated using cerebrospinal fluid analysis and positron emission tomography imaging. These methods are invasive or costly, limiting their widespread clinical utility. Blood-based biomarkers offer a promising alternative due to accessibility, cost-effectiveness, and feasibility for large-scale screening. Among blood-based biomarkers, plasma glial fibrillary acidic protein (GFAP) levels have gained interest in identifying individuals at risk of AD at preclinical stages. However, significant challenges remain, including methodological inconsistencies, analytical variability, and the need for standardisation across immunoassay platforms to ensure the clinical applicability of plasma GFAP measurement in AD diagnosis. Additionally, the specificity of GFAP for AD needs further evaluation, as increased plasma levels are also observed in other diseases. Similar issues are found with p-tau 217, the blood biomarker candidate for AD that has received the most attention. This review summarises the role of GFAP in the neuropathology of AD, provides evidence on plasma GFAP as an early blood biomarker for AD and identifies key knowledge gaps that need to be addressed. Future advancements in assay development and large-scale longitudinal studies are essential to validate its diagnostic and prognostic potential for community-based AD screening.
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
High risk of obstructive sleep apnoea is associated with higher baseline plasma glial fibrillary acidic protein and predicts decline in levels over time in cognitively unimpaired older adults
Background: Findings from animal studies report links between obstructive sleep apnoea (OSA) models and elevated glial fibrillary acidic protein (GFAP). In humans, elevated plasma GFAP, reflecting reactive astrogliosis, is considered an early event in the Alzheimer’s disease (AD) continuum. The current study investigated whether OSA risk predicts the slope of plasma GFAP in cognitively unimpaired older adults.Method: Linear mixed effect model analyses were conducted on 70 cognitively unimpaired older adult (M = 73.1, SD = 5.2, 57.1% female) participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Ageing. Individuals completed the well‐validated STOP‐Bang questionnaire to assess OSA risk (Low; Intermediate; High), and underwent positron emission tomography (PET) to quantify brain Aβ burden. Plasma GFAP was measured using the Simoa® platform over three timepoints (range 30.06 ‐ 99.45 months). The model included, a random intercept, a three‐way interaction between OSA risk, baseline brain Aβ status and time, adjusting for Apolipoprotein E (APOE) ε4 status, sex, baseline age, and baseline body mass index.Result: High risk of OSA and high brain Aβ (>25 Centiloids) were independently associated with higher baseline plasma GFAP and forecast a negative longitudinal plasma GFAP trajectory.Conclusion: These novel findings suggest that OSA mechanisms, independent of prior brain Aβ accumulation, may contribute to early reactive astrogliosis in cognitively unimpaired older adults. Additionally, a decline in plasma GFAP was observed during the preclinical period, both in those at high risk of OSA and those at greater risk of AD due to high brain Aβ.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S24)
Open AccessHigh risk of obstructive sleep apnoea is associated with higher baseline plasma glial fibrillary acidic protein and predicts decline in levels over time in cognitively unimpaired older adults
Background: Findings from animal studies report links between obstructive sleep apnoea (OSA) models and elevated glial fibrillary acidic protein (GFAP). In humans, elevated plasma GFAP, reflecting reactive astrogliosis, is considered an early event in the Alzheimer’s disease (AD) continuum. The current study investigated whether OSA risk predicts the slope of plasma GFAP in cognitively unimpaired older adults.Method: Linear mixed effect model analyses were conducted on 70 cognitively unimpaired older adult (M = 73.1, SD = 5.2, 57.1% female) participants of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Ageing. Individuals completed the well‐validated STOP‐Bang questionnaire to assess OSA risk (Low; Intermediate; High), and underwent positron emission tomography (PET) to quantify brain Aβ burden. Plasma GFAP was measured using the Simoa® platform over three timepoints (range 30.06 ‐ 99.45 months). The model included, a random intercept, a three‐way interaction between OSA risk, baseline brain Aβ status and time, adjusting for Apolipoprotein E (APOE) ε4 status, sex, baseline age, and baseline body mass index.Result: High risk of OSA and high brain Aβ (>25 Centiloids) were independently associated with higher baseline plasma GFAP and forecast a negative longitudinal plasma GFAP trajectory.Conclusion: These novel findings suggest that OSA mechanisms, independent of prior brain Aβ accumulation, may contribute to early reactive astrogliosis in cognitively unimpaired older adults. Additionally, a decline in plasma GFAP was observed during the preclinical period, both in those at high risk of OSA and those at greater risk of AD due to high brain Aβ.
- 22 August 2022
- Published by Springer Nature in The EMBO Journal
- Vol. 41 (18) , e10242
Tau target identification reveals NSF‐dependent effects on AMPA receptor trafficking and memory formation
Microtubule-associated protein tau is a central factor in Alzheimer's disease and other tauopathies. However, the physiological functions of tau are unclear. Here, we used proximity-labelling proteomics to chart tau interactomes in primary neurons and mouse brains in vivo. Tau interactors map onto pathways of cytoskeletal, synaptic vesicle and postsynaptic receptor regulation and show significant enrichment for Parkinson's, Alzheimer's and prion disease. We find that tau interacts with and dose-dependently reduces the activity of N-ethylmaleimide sensitive fusion protein (NSF), a vesicular ATPase essential for AMPA-type glutamate receptor (AMPAR) trafficking. Tau-deficient (tau-/- ) neurons showed mislocalised expression of NSF and enhanced synaptic AMPAR surface levels, reversible through the expression of human tau or inhibition of NSF. Consequently, enhanced AMPAR-mediated associative and object recognition memory in tau-/- mice is suppressed by both hippocampal tau and infusion with an NSF-inhibiting peptide. Pathologic mutant tau from mouse models or Alzheimer's disease significantly enhances NSF inhibition. Our results map neuronal tau interactomes and delineate a functional link of tau with NSF in plasticity-associated AMPAR-trafficking and memory.
- 22 August 2022
- Published by Springer Nature in The EMBO Journal
- Vol. 41 (18) , e10242
Tau target identification reveals NSF‐dependent effects on AMPA receptor trafficking and memory formation
Microtubule-associated protein tau is a central factor in Alzheimer's disease and other tauopathies. However, the physiological functions of tau are unclear. Here, we used proximity-labelling proteomics to chart tau interactomes in primary neurons and mouse brains in vivo. Tau interactors map onto pathways of cytoskeletal, synaptic vesicle and postsynaptic receptor regulation and show significant enrichment for Parkinson's, Alzheimer's and prion disease. We find that tau interacts with and dose-dependently reduces the activity of N-ethylmaleimide sensitive fusion protein (NSF), a vesicular ATPase essential for AMPA-type glutamate receptor (AMPAR) trafficking. Tau-deficient (tau-/- ) neurons showed mislocalised expression of NSF and enhanced synaptic AMPAR surface levels, reversible through the expression of human tau or inhibition of NSF. Consequently, enhanced AMPAR-mediated associative and object recognition memory in tau-/- mice is suppressed by both hippocampal tau and infusion with an NSF-inhibiting peptide. Pathologic mutant tau from mouse models or Alzheimer's disease significantly enhances NSF inhibition. Our results map neuronal tau interactomes and delineate a functional link of tau with NSF in plasticity-associated AMPAR-trafficking and memory.
- Open Access
- 8 July 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (27) , eabl8809
Alzheimer’s disease: Ablating single master site abolishes tau hyperphosphorylation
Hyperphosphorylation of the neuronal tau protein is a hallmark of neurodegenerative tauopathies such as Alzheimer’s disease. A central unanswered question is why tau becomes progressively hyperphosphorylated. Here, we show that tau phosphorylation is governed by interdependence— a mechanistic link between initial site-specific and subsequent multi-site phosphorylation. Systematic assessment of site interdependence identified distinct residues (threonine-50, threonine-69, and threonine-181) as master sites that determine propagation of phosphorylation at multiple epitopes. CRISPR point mutation and expression of human tau in Alzheimer’s mice showed that site interdependence governs physiologic and amyloid-associated multi-site phosphorylation and cognitive deficits, respectively. Combined targeting of master sites and p38α, the most central tau kinase linked to interdependence, synergistically ablated hyperphosphorylation. In summary, our work delineates how complex tau phosphorylation arises to inform therapeutic and biomarker design for tauopathies.
- 8 July 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (27) , eabl8809
Open AccessAlzheimer’s disease: Ablating single master site abolishes tau hyperphosphorylation
Hyperphosphorylation of the neuronal tau protein is a hallmark of neurodegenerative tauopathies such as Alzheimer’s disease. A central unanswered question is why tau becomes progressively hyperphosphorylated. Here, we show that tau phosphorylation is governed by interdependence— a mechanistic link between initial site-specific and subsequent multi-site phosphorylation. Systematic assessment of site interdependence identified distinct residues (threonine-50, threonine-69, and threonine-181) as master sites that determine propagation of phosphorylation at multiple epitopes. CRISPR point mutation and expression of human tau in Alzheimer’s mice showed that site interdependence governs physiologic and amyloid-associated multi-site phosphorylation and cognitive deficits, respectively. Combined targeting of master sites and p38α, the most central tau kinase linked to interdependence, synergistically ablated hyperphosphorylation. In summary, our work delineates how complex tau phosphorylation arises to inform therapeutic and biomarker design for tauopathies.
- Open Access
- 14 August 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-16
Contribution of endogenous antibodies to learning deficits and astrocytosis in human P301S mutant tau transgenic mice
Antibodies have been explored extensively as a potential therapeutic for Alzheimer’s disease, where amyloid-β (Aβ) peptides and the tau protein deposit in patient brains. While the major focus of antibody-based therapy development was on Aβ, arguably with limited success in clinical trials, targeting tau has become an emerging strategy, possibly extending therapies to dementias with isolated tau pathology. Interestingly, low titres of autoantibodies to pathological tau have been described in humans and transgenic mouse models, but their pathophysiological relevance remained elusive. Here, we used two independent approaches to deplete the B-cell lineage and hence antibody formation in human P301S mutant tau transgenic mice, TAU58/2. TAU58/2 mice were either crossed with the B-cell-deficient Ighm knockout line (muMT−/−) or treated with anti-CD20 antibodies that target B-cell precursors. In both models, B-cell depletion significantly reduced astrocytosis in TAU58/2 mice. Only when B-cells were absent throughout life, in TAU58/2.muMT−/− mice, were spatial learning deficits moderately aggravated while motor performance improved as compared to B-cell-competent TAU58/2 mice. This was associated with changes in brain region-specific tau solubility. No other relevant behavioural or neuropathological changes were observed in TAU58/2 mice in the absence of B-cells/antibodies. Taken together, our data suggests that the presence of antibodies throughout life contributes to astrocytosis in TAU58/2 mice and limits learning deficits, while other deficits and neuropathological changes appear to be independent of the presence of B-cells/antibodies.
- 14 August 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-16
Open AccessContribution of endogenous antibodies to learning deficits and astrocytosis in human P301S mutant tau transgenic mice
Antibodies have been explored extensively as a potential therapeutic for Alzheimer’s disease, where amyloid-β (Aβ) peptides and the tau protein deposit in patient brains. While the major focus of antibody-based therapy development was on Aβ, arguably with limited success in clinical trials, targeting tau has become an emerging strategy, possibly extending therapies to dementias with isolated tau pathology. Interestingly, low titres of autoantibodies to pathological tau have been described in humans and transgenic mouse models, but their pathophysiological relevance remained elusive. Here, we used two independent approaches to deplete the B-cell lineage and hence antibody formation in human P301S mutant tau transgenic mice, TAU58/2. TAU58/2 mice were either crossed with the B-cell-deficient Ighm knockout line (muMT−/−) or treated with anti-CD20 antibodies that target B-cell precursors. In both models, B-cell depletion significantly reduced astrocytosis in TAU58/2 mice. Only when B-cells were absent throughout life, in TAU58/2.muMT−/− mice, were spatial learning deficits moderately aggravated while motor performance improved as compared to B-cell-competent TAU58/2 mice. This was associated with changes in brain region-specific tau solubility. No other relevant behavioural or neuropathological changes were observed in TAU58/2 mice in the absence of B-cells/antibodies. Taken together, our data suggests that the presence of antibodies throughout life contributes to astrocytosis in TAU58/2 mice and limits learning deficits, while other deficits and neuropathological changes appear to be independent of the presence of B-cells/antibodies.
- 29 July 2020
- Published by Springer Nature in Acta Neuropathologica
- Vol. 140 (3) , 279-294
Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ
Hyperphosphorylation of the neuronal tau protein contributes to Alzheimer’s disease (AD) by promoting tau pathology and neuronal and cognitive deficits. In contrast, we have previously shown that site-specific tau phosphorylation can inhibit toxic signals induced by amyloid-β (Aβ) in mouse models. The post-synaptic mitogen-activated protein (MAP) kinase p38γ mediates this site-specific phosphorylation on tau at Threonine-205 (T205). Using a gene therapeutic approach, we draw on this neuroprotective mechanism to improve memory in two Aβ-dependent mouse models of AD at stages when advanced memory deficits are present. Increasing activity of post-synaptic kinase p38γ that targets T205 in tau reduced memory deficits in symptomatic Aβ-induced AD models. Reconstitution experiments with wildtype human tau or phosphorylation-deficient tauT205A showed that T205 modification is critical for downstream effects of p38γ that prevent memory impairment in APP-transgenic mice. Furthermore, genome editing of the T205 codon in the murine Mapt gene showed that this single side chain in endogenous tau critically modulates memory deficits in APP-transgenic Alzheimer’s mice. Ablating the protective effect of p38γ activity by genetic p38γ deletion in a tau transgenic mouse model that expresses non-pathogenic tau rendered tau toxic and resulted in impaired memory function in the absence of human Aβ. Thus, we propose that modulating neuronal p38γ activity serves as an intrinsic tau-dependent therapeutic approach to augment compromised cognition in advanced dementia.
- 29 July 2020
- Published by Springer Nature in Acta Neuropathologica
- Vol. 140 (3) , 279-294
Reduction of advanced tau-mediated memory deficits by the MAP kinase p38γ
Hyperphosphorylation of the neuronal tau protein contributes to Alzheimer’s disease (AD) by promoting tau pathology and neuronal and cognitive deficits. In contrast, we have previously shown that site-specific tau phosphorylation can inhibit toxic signals induced by amyloid-β (Aβ) in mouse models. The post-synaptic mitogen-activated protein (MAP) kinase p38γ mediates this site-specific phosphorylation on tau at Threonine-205 (T205). Using a gene therapeutic approach, we draw on this neuroprotective mechanism to improve memory in two Aβ-dependent mouse models of AD at stages when advanced memory deficits are present. Increasing activity of post-synaptic kinase p38γ that targets T205 in tau reduced memory deficits in symptomatic Aβ-induced AD models. Reconstitution experiments with wildtype human tau or phosphorylation-deficient tauT205A showed that T205 modification is critical for downstream effects of p38γ that prevent memory impairment in APP-transgenic mice. Furthermore, genome editing of the T205 codon in the murine Mapt gene showed that this single side chain in endogenous tau critically modulates memory deficits in APP-transgenic Alzheimer’s mice. Ablating the protective effect of p38γ activity by genetic p38γ deletion in a tau transgenic mouse model that expresses non-pathogenic tau rendered tau toxic and resulted in impaired memory function in the absence of human Aβ. Thus, we propose that modulating neuronal p38γ activity serves as an intrinsic tau-dependent therapeutic approach to augment compromised cognition in advanced dementia.
- 17 July 2020
- Published by Wiley in Journal of Neurochemistry
- Vol. 159 (2) , 389-402
Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that currently has no cure. Identifying biochemical changes associated with neurodegeneration prior to symptom onset, will provide insight into the biological mechanisms associated with neurodegenerative processes, that may also aid in identifying potential drug targets. The current study therefore investigated associations between plasma neurofilament light chain (NF‐L), a marker of neurodegeneration, with plasma metabolites that are products of various cellular processes. Plasma NF‐L, measured by ultrasensitive Single molecule array (Simoa) technology (Quanterix) and plasma metabolites, measured by mass‐spectrometry (AbsoluteIDQ® p400HR kit, BIOCRATES), were assessed in the Kerr Anglican Retirement Village Initiative in Ageing Health (KARVIAH) cohort comprising 100 cognitively normal older adults. Metabolites belonging to biogenic amine (creatinine, symmetric dimethylarginine, asymmetric dimethylarginine; ADMA, kynurenine, trans‐4‐hydroxyproline), amino acid (citrulline, proline, arginine, asparagine, phenylalanine, threonine) and acylcarnitine classes were observed to have positive correlations with plasma NF‐L, suggesting a link between neurodegeneration and biological pathways associated with neurotransmitter regulation, nitric oxide homoeostasis, inflammation and mitochondrial function. Additionally, after stratifying participants based on low/high brain amyloid‐β load (Aβ ±) assessed by positron emission tomography, while creatinine, SDMA and citrulline correlated with NF‐L in both Aβ‐ and Aβ+ groups, ADMA, proline, arginine, asparagine, phenylalanine and acylcarnitine species correlated with NF‐L only in the Aβ+ group after adjusting for confounding variables, suggesting that the association of these metabolites with neurodegeneration may be relevant to AD‐related neuropathology. Metabolites identified to be associated with plasma NF‐L may have the potential to serve as prognostic markers for neurodegenerative diseases, however, further studies are required to validate the current findings in an independent cohort, both cross‐sectionally and longitudinally. image
- 17 July 2020
- Published by Wiley in Journal of Neurochemistry
- Vol. 159 (2) , 389-402
Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that currently has no cure. Identifying biochemical changes associated with neurodegeneration prior to symptom onset, will provide insight into the biological mechanisms associated with neurodegenerative processes, that may also aid in identifying potential drug targets. The current study therefore investigated associations between plasma neurofilament light chain (NF‐L), a marker of neurodegeneration, with plasma metabolites that are products of various cellular processes. Plasma NF‐L, measured by ultrasensitive Single molecule array (Simoa) technology (Quanterix) and plasma metabolites, measured by mass‐spectrometry (AbsoluteIDQ® p400HR kit, BIOCRATES), were assessed in the Kerr Anglican Retirement Village Initiative in Ageing Health (KARVIAH) cohort comprising 100 cognitively normal older adults. Metabolites belonging to biogenic amine (creatinine, symmetric dimethylarginine, asymmetric dimethylarginine; ADMA, kynurenine, trans‐4‐hydroxyproline), amino acid (citrulline, proline, arginine, asparagine, phenylalanine, threonine) and acylcarnitine classes were observed to have positive correlations with plasma NF‐L, suggesting a link between neurodegeneration and biological pathways associated with neurotransmitter regulation, nitric oxide homoeostasis, inflammation and mitochondrial function. Additionally, after stratifying participants based on low/high brain amyloid‐β load (Aβ ±) assessed by positron emission tomography, while creatinine, SDMA and citrulline correlated with NF‐L in both Aβ‐ and Aβ+ groups, ADMA, proline, arginine, asparagine, phenylalanine and acylcarnitine species correlated with NF‐L only in the Aβ+ group after adjusting for confounding variables, suggesting that the association of these metabolites with neurodegeneration may be relevant to AD‐related neuropathology. Metabolites identified to be associated with plasma NF‐L may have the potential to serve as prognostic markers for neurodegenerative diseases, however, further studies are required to validate the current findings in an independent cohort, both cross‐sectionally and longitudinally. image
- Open Access
- 30 June 2020
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 76 (1) , 291-301
Serum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-β Load
Background/Objective: Hepcidin, an iron-regulating hormone, suppresses the release of iron by binding to the iron exporter protein, ferroportin, resulting in intracellular iron accumulation. Given that iron dyshomeostasis has been observed in Alzheim
- 30 June 2020
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 76 (1) , 291-301
Open AccessSerum Hepcidin Levels in Cognitively Normal Older Adults with High Neocortical Amyloid-β Load
Background/Objective: Hepcidin, an iron-regulating hormone, suppresses the release of iron by binding to the iron exporter protein, ferroportin, resulting in intracellular iron accumulation. Given that iron dyshomeostasis has been observed in Alzheim